73-8.
201. Scheinert D, Duda S, Zeller T, Krankenberg H, Ricke J, Bosiers M,
et al. The LEVANT I (Lutonix paclitaxel-coated balloon for the
prevention of femoropopliteal restenosis) trial for femoropopliteal
revascularization: ﬁrst-in-human randomized trial of low-dose drugcoated balloon versus uncoated balloon angioplasty. JACC Cardiovasc Interv 2014;7:10-9.
202. Tepe G, Zeller T, Albrecht T, Heller S, Schwarzwalder U, Beregi JP,
et al. Local delivery of paclitaxel to inhibit restenosis during angioplasty of the leg. N Engl J Med 2008;358:689-99.
203. Werk M, Langner S, Reinkensmeier B, Boettcher HF, Tepe G,
Dietz U, et al. Inhibition of restenosis in femoropopliteal arteries:
paclitaxel-coated versus uncoated balloon: femoral paclitaxel randomized pilot trial. Circulation 2008;118:1358-65.
204. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, et al.
Paclitaxel-eluting stents show superiority to balloon angioplasty and
bare metal stents in femoropopliteal disease: twelve-month Zilver PTX
randomized study results. Circ Cardiovasc Interv 2011;4:495-504.
205. Cioppa A, Stabile E, Popusoi G, Salemme L, Cota L, Pucciarelli A,
et al. Combined treatment of heavy calciﬁed femoro-popliteal lesions
using directional atherectomy and a paclitaxel coated balloon: oneyear single centre clinical results. Cardiovasc Revasc Med 2012;13:
219-23.
206. Hayes DJ Jr, Dougherty MJ, Call